Jason Davies Email & Phone Number

United Kingdom

• Launch excellence, commercial operations scale-up & GTM model, opportunity/business case assessment, strategy development, business/brand planning and target product profile development.• Consulting, interim leadership, strategic guidance, and expert advice for emerging and established pharmaceutical companies, start-up/scaling biotech’s, and investors (PE/VC funds).

Luzern/ Zug, Ch

• Consulting, interim leadership, strategic guidance, and expert advice for emerging and established pharmaceutical companies, start-up/scaling biotech’s, and investors (PE/VC funds).

Miami, Fl, Us

Leadership of the Veru International Business across EMEA, UK, Canada, Asia Pacific and Latin America, sitting as a member of the Executive Leadership Team.Driving the development and execution of a GTM strategy for a new franchise with the creation of the affiliate vs commercial partner model across prioritised, sequenced marketsCritical responsibilities span creating the optimal external customer/channel and supply chain model plus building strategic senior external relationships (e.g., Governments, MoH, PAGs, KOLs). Held senior level dialogue at the EU Commission and with key markets such as Germany, Netherlands, Italy, Spain, Belgium, Israel, UAE, Singapore, Canada, Switzerland, and the UK.Translating clinical/economic benefits and determining the market access requirements for each target country to ensure rapid, sustainable and value driven reimbursement.Building relationships and strategic partnerships with commercial partners/distributors across the international footprint; adopting a clear evaluation, due diligence, and partnership agreement approach.Development of critical capabilities and people structures to attract, retain, and empower talent. Major focus on driving clear, operational alignment with appropriate legal, regulatory and compliance requirements.

Beerse, Be

Created and led a new organisational function to drive a step change in launch strategy/execution across the full pharmaceutical portfolio in the EMEA region.Major focus on proactively tackling the changing competitive landscape, harnessing an increasing complex, growing portfolio, and ultimately driving optimal impact for patients and our customers through data driven investments and strategic choices.

Beerse, Be

EMEA leadership of J&J’s largest ever acquisition, ACTELION, as a major organizational step into the Rare Disease operating model. Leadership accountability for the Rare Disease/Cardiopulmonary strategy with a strong focus on driving effective integration into BAU, accelerating the growth of current indications.Driving optimal readiness for future launches and partnering with portfolio business development to prioritize and assess opportunities that are of priority interest to Janssen EMEA.

Raritan, New Jersey, Us

Leadership of the Immunology Strategy Development for Immunology across the Emerging Markets (BRICMT). Worked in partnership with R&D and business development to prioritize and assess new Immunology opportunities for the organization.

Raritan, New Jersey, Us

Leadership of the Global Commercial Team in the development and execution of integrated launch strategies across regions and markets. Worked in partnership with R&D and the wider Disease Area Stronghold (DAS) management, providing commercial leadership to Compound Development Teams to ensure early and later stage development of highly differentiated products with strong evidence-based value propositions. Responsible for leading the commercial work streams, in partnership with business development, to prioritize and assess new opportunities for the organization.

Raritan, New Jersey, Us

UK Management Board Director, leading business units across the Diabetes, Oncology & Haematology portfolio with previous responsibility for Immunology & Hepatitis C. Provided active leadership for multiple launches into the UK market (Invokana, Imbruvica, Zytiga etc) with a clear record of out-performing competitor benchmarks. Led the integration of field based Market Access teams into a new commercial model with a clear focus on driving agility, accountability and alignment. Strong UK voice in EMEA/Global discussions through a developed network across disease area strongholds (DAS). Senior NHS customer relationships with engagement focused on aligning NHS/Janssen priorities on patient focused initiatives, policy change and major procurement decisions.

Raritan, New Jersey, Us

Delivered the strongest launch of an Oncology drug in the UK as measured by IMS and re-shaped the haematology strategy to effect a change from flat to +34% growth.

Raritan, New Jersey, Us

Tasked with building a new Oncology/Haematology Business Unit with full responsibility for creating a new resourcing model, new national team hire, significant brand launches and full P&L accountability.

Raritan, New Jersey, Us

Leadership of the team development and execution of marketing strategies for in-line and pre-launch brands across prostate cancer, ovarian cancer and multiple myeloma.

Raritan, New Jersey, Us

Led the team development of Market Access strategies for all new Janssen UK launches across a 5 year horizon to deliver robust value propositions & compelling tools to effectively communicate the value of our new technologies to key decision-makers. Provided commercial expertise into the HTA planning process, building strong collaborative relationships across Outcomes Research in UK and Europe. Led the evolutionary development of the Janssen UK launch/market access planning processes to drive business alignment and industry leading excellence in market access.

Raritan, New Jersey, Us

Led, motivated and coached a team of Health Economy Liaison Managers across the South UK, supporting the creation of the Market Access department in the new Janssen business model. Created & chaired UK Value Team for the Antibiotics. HIV & Hepatitis C pipeline, representing the UK at Global/EMEA Market Access meetings to shape and influence priorities. Market Access lead for HIV, Pain Management, Antibiotics & Hepatitis C portfolios.

New Brunswick, Nj, Us

Janssen, Nov 2005 – May 2007, Healthcare Development – South UK Team Janssen, Mar 2005 – Oct 2005, Product Manager – Neuroscience Janssen, May 2002 – Feb 2005, Business Development – South UK Team LeadershipJanssen, Jan 2001 – Apr 2002, Regional Business Manager Quintiles, Mar 1999 – Dec 2000, Regional Business Manager Wyeth, Jan 1997 – Feb 1999, Field Trainer & Oncology Sales Specialist Schering-Plough, Jul 1993 – Dec 1996, Account Manager